Valuation
Is the price right?3/3 inputs reported · High confidence
Weaker than most peers on:
- ▼ Earnings yield
- ▼ EBITDA yield
Behind the score
Sector-normalized EBITDA, earnings, and free cash flow yields.
Bringing the fundamentals into focus…
Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026
3/3 inputs reported · High confidence
Weaker than most peers on:
Sector-normalized EBITDA, earnings, and free cash flow yields.
Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.
2/3 inputs reported · Partial data
Weaker than most peers on:
Return on invested capital, operating margin, and return on assets.
3/3 inputs reported · High confidence
Mixed versus peers:
Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
No major changes
Worth watching: Scholar Rock is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.
| Previous quarter | Latest quarter | Change | |
|---|---|---|---|
| Revenue (12 months) | 0 USD | 0 USD | — |
| Net income (12 months) | −408.8M USD | −408.7M USD | −0.0% |
| Free cash flow (12 months) | −303.9M USD | −297.0M USD | −2.3% |
| Debt | 196.6M USD | 196.2M USD | −0.2% |
| Cash | 430.5M USD | 437.1M USD | +1.5% |
| Shares outstanding | 119.8M | 121.8M | +1.6% |
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Valuations in Biotechnology are within their usual range since 2016.
Earnings-based measures are left out for now because many companies in Biotechnology are losing money.
| Key ratios | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | Change |
|---|---|---|---|---|---|---|
| Operating margin | -690.5% | -404.8% | — | — | — | — |
| Net margin | -700.5% | -405.2% | — | — | — | — |
| Return on assets (ROA) | -43.3% | -37.6% | -53.3% | -51.9% | -93.5% | ▼ 42 pts |
| Return on equity (ROE) | -76.6% | -51.7% | -73.6% | -66.8% | -154.0% | ▼ 87 pts |
| Free cash flow margin | -701.7% | -403.0% | — | — | — | — |
| Current ratio | 4.13× | 9.01× | 8.80× | 9.61× | 6.95× | ▼ 28% |
| Debt to equity | 0.31× | 0.20× | 0.23× | 0.14× | 0.41× | ▲ 199% |
| Interest coverage | -61.87× | -28.59× | -26.35× | -36.87× | -55.80× | ▼ 51% |
Price history is added with the daily price update and will appear after the next one.